Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma
Vaccination With Idiotype-KLH Loaded Dendritic Cells. A Phase I Study for Patients With Multiple Myeloma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Dresden, Germany, 01307
- University Hospital Dresden
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- multiple myeloma
- stage I (Salmon & Durie)
- no cytoreductive pre-treatment
Exclusion Criteria:
- myeloma stages II-III
- asecretory disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: s.c. vaccination
vaccine given subcutaneously
|
Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks
|
|
EXPERIMENTAL: i.v. vaccination
vaccines are given intravenously
|
Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Specific T-cell proliferation/cytokine secretion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
number of T cells
Time Frame: pre and post vaccination
|
pre and post vaccination
|
|
monoclonal protein
Time Frame: pre and post vaccination
|
pre and post vaccination
|
|
plasmacells in bone marrow
Time Frame: pre and post vaccination
|
pre and post vaccination
|
|
vital signs
Time Frame: pre and post vaccination
|
pre and post vaccination
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Susanne Gretzinger, MD, University Hospital Dresden
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Plasmacytoma
- Physiological Effects of Drugs
- Immunologic Factors
- Immunoglobulin Idiotypes
Other Study ID Numbers
Other Study ID Numbers
- MyelomVak
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.